VTRS 비아트리스 · Viatris Inc.

영업이익률 개선(+17.8%p). 11/5 실적 발표 예정.

종가$18.45
시가총액$214억
업종헬스케어
다음 실적 발표2026-11-05
매출 성장(최근 4분기)+4.4%
영업이익률-0.6%
애널리스트 순상향률+18%
목표가 상승여력+7.9%
공매도 거래 비중43%
유명 투자자 보유1곳
1년 수익률+85%

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabo

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목